1. 191PD_PR9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. (23rd October 2018) Authors: Conte, P F; Guarneri, V; Bisagni, G; Piacentini, F; Brandes, A A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Frassoldati, A; Musolino, A; Garrone, O; Taverniti, C; Rimanti, A; Sarti, S; Rubino, D; Bologna, A; Vicini, R; Balduzzi, S; D'Amico, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. (17th January 2019) Authors: Dieci, M V; Conte, P; Bisagni, G; Brandes, A A; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S Journal: Annals of oncology Issue: Volume 30:Number 3(2019) Page Start: 418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗